Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 5/12/2019
SIETES contiene 92850 citas

 
 
 1 a 12 de 12 
Presentar resultados
Seleccionar todas
1.Enlace a cita original
Günthard HF, Saag MS, Benson CA, Del Río C, Eron JJ, Gallant JE, Hoy JF, Mugavero MJ, Sax PE, Thompson MA, Gandhi RT, Landovitz RJ, Smith DM, Jacobsen DM, Volberding PA. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society - USA Panel. JAMA 2016;316:191-210. [Ref.ID 100629]
2. Cita con resumen
Mollan KR, Smurzynski M, Eron JJ, Daar ES, Campbel TB, Sax PE, Gulick RM, O'Keefe L, Robertson KR, Tierney C. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med 2014;161:1-10. [Ref.ID 97795]
3.
Eron JJ, Young B, Cooper DA, Youle M, DeJesus E, Andrade-Villanueva J, Workman C, Zajdenverg R, Fätkenheuer G, Berger DS, Kumar PN, Rodgers AJ, Shaughnessy MA, Walker ML, Barnard RJO, Miller MD, DiNubile MJ, Nguyen B-Y, Leavitt R, Xu X, Sklar P, for the SWITCHMRK1 and 2 investigators. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010;375:396-407. [Ref.ID 87807]
4.Tiene citas relacionadas Cita con resumen
Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Goedert JJ, Benson CA, Collier AC, Van Rompaey SE, Crane HM, McKaig RG, Lau B, Freeman AM, Moore RD, for the NA-ACCORD Investigators. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009;360:1815-26. [Ref.ID 85716]
5.Tiene citas relacionadas Cita con resumen
Lalezari JP, Henry K, O'Hearn M, Montaner JSG, Piliero P J, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ, Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M, for the TORO 1 Study Group. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-85. [Ref.ID 66381]
6.
Pilcher C D, McPherson JT, Leone PA, Smurzynski M, Owen-O'Dowd J, Peace-Brewer A L, Harris J, Hicks CB, Eron JJ, Fiscus SA. Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing population. JAMA 2002;288:216-21. [Ref.ID 62739]
7.Tiene citas relacionadas
Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wehat LJ, Mitsuyasu R T, Gulick RM, Valentine FT, Aberg JA, Rogers M D, Karol CN, Saah AJ, Lewis RH, Bessen LJ, Brosgart C, DeGruttola V, Mellors JW, for the AIDS Clinical Trials Group 398 Study Team. Dual vs single protease inhibitor therapy following antiretroviral treatment failure. A randomized trial. JAMA 2002;288:169-80. [Ref.ID 62734]
8. Cita con resumen
Gulick RM, Mellors JW, Havlir D, Eron JJ, Meibohm A, Condra JH, Valentine FT, McMahon D, Gonzalez C, Jonas L, Eimini EA, Chodakewitz JA, Isaacs R, Richman D D. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med 2000;133:35-9. [Ref.ID 51705]
9.
Rublein J C, Eron JJ, Butts JD, Raasch R H. Discontinuation rates for protease inhibitor regimens containing ritonavir 600 mg versus ritonavir 400 mg plus saquinavir 400 mg. Ann Pharmacother 1999;33:899-905. [Ref.ID 47018]
10.
Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Jonas L, Meibohm A, Holder D, Schleif WA, Condra JH, Emini EA, Isaacs R, Chodakewitz JA, Richman D D. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection. JAMA 1998;280:35-41. [Ref.ID 39084]
11.
Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman D D, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz JA. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9. [Ref.ID 34639]
12.
Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Feinberg JE, Balfour HH, Deyton LR, Chodakewitz JA, Fischl MA, for the AIDS Clinical Trials Group 320 Study Team. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33. [Ref.ID 34638]
Seleccionar todas
 
 1 a 12 de 12